Zolinza and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Zolinza (vorinostat), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lipitor, and have Mycosis fungoides.

The study is created by eHealthMe based on reports of 943 people who have side effects when taking Zolinza from the FDA, and is updated regularly.

What is Zolinza?

Zolinza has active ingredients of vorinostat. eHealthMe is studying from 949 Zolinza users. Check the latest studies of Zolinza.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 24, 2026

943 people reported to have side effects when taking Zolinza.
Among them, 72 people (7.64%) died.

Among these 72 people:

How long have people been on Zolinza when they died? *

What is the gender of people who died when taking Zolinza? *

female: 23.08 %
male: 76.92 %

What is the age of people who died when taking Zolinza? *

What are other drugs people take besides Zolinza? *

Lipitor: 5 people, 6.94%
Acetaminophen And Hydrocodone Bitartrate: 4 people, 5.56%
Bexarotene: 4 people, 5.56%
Alprazolam: 4 people, 5.56%
Amlodipine: 4 people, 5.56%
Doxil: 4 people, 5.56%
Diflucan: 3 people, 4.17%
Lamisil: 3 people, 4.17%
Oxycodone: 3 people, 4.17%
Ondansetron: 3 people, 4.17%

What are other side effects people have before they died? *

Thrombocytopenia (decrease of platelets in blood): 11 people, 15.28%
Nausea (feeling of having an urge to vomit): 8 people, 11.11%
Fever: 6 people, 8.33%
Hepatic Function Abnormal: 5 people, 6.94%
Fibrin D Dimer Increased: 5 people, 6.94%
Fatigue (feeling of tiredness): 4 people, 5.56%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 4 people, 5.56%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 5.56%
Renal Impairment (severely reduced kidney function): 4 people, 5.56%
Hyperglycemia (high blood sugar): 3 people, 4.17%

What are the existing conditions these people have? *

Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 27 people, 37.50%
Metastases To Central Nervous System (cancer spreads to central nervous system): 6 people, 8.33%
Multiple Myeloma (cancer of the plasma cells): 6 people, 8.33%
T-Cell Lymphoma (a blood cell cancer): 4 people, 5.56%
Diabetes: 3 people, 4.17%
Body Tinea (ringworm of the body): 3 people, 4.17%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 4.17%
Constipation: 3 people, 4.17%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 2.78%
Gastritis (inflammation of stomach): 2 people, 2.78%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zolinza:

Zolinza (949 reports)

Expand to all the drugs that have ingredients of vorinostat:

Death and drugs with ingredients of vorinostat (134 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zolinza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,114 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vorinostat (the active ingredients of Zolinza) and Zolinza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.